


PHARMACEUTICAL 2022

Longboard Pharmaceuticals Inc. Rank 143 of 475





PHARMACEUTICAL 2022

Longboard Pharmaceuticals Inc. Rank 143 of 475

The relative strengths and weaknesses of Longboard Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Longboard Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 245% points. The greatest weakness of Longboard Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 1.2%, being 278% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	108,384
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,444
Liabilities, Non-Current	0
Other Assets	554
Other Compr. Net Income	-164
Other Expenses	0
Other Liabilities	0
Other Net Income	42
Property and Equipment	14
Research and Development	19,774
Revenues	0
Selling, General and Administrative Expense	8,065

Output Variable	Value in 1000 USD
Assets	108,952
Liabilities	5,444
Expenses	27,839
Stockholders Equity	103,508
Net Income	-27,797
Comprehensive Net Income	-27,879
Economic Capital Ratio	1.2%